Solifenacin succinate suspension

Phase 3Completed
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Urinary Bladder, Overactive

Conditions

Urinary Bladder, Overactive

Trial Timeline

Oct 4, 2012 → Oct 8, 2014

About Solifenacin succinate suspension

Solifenacin succinate suspension is a phase 3 stage product being developed by Astellas Pharma for Urinary Bladder, Overactive. The current trial status is completed. This product is registered under clinical trial identifier NCT01655069. Target conditions include Urinary Bladder, Overactive.

What happened to similar drugs?

20 of 20 similar drugs in Urinary Bladder, Overactive were approved

Approved (20) Terminated (1) Active (0)
Levofloxacin + LevofloxacinDr. Reddy's LaboratoriesApproved
SolifenacinAstellas PharmaApproved
Tamsulosin + SolifenacinAstellas PharmaApproved
Alpha blocker + placebo + solifenacinAstellas PharmaApproved
solifenacin succinate + PlaceboAstellas PharmaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01655069Phase 3Completed

Competing Products

20 competing products in Urinary Bladder, Overactive

See all competitors